Subscribe to our free weekly newsletter
Send news

News tags

mental health  physical activity  earthquake  vacancies  families  public health  children  funding  poverty  health determinants  social  Community development  planning  employment  healthy cities  volunteers  newsletter  youth  volunteering  nutrition  employment opportunity  housing  alcohol and drugs  maori  community engagement  rebuilding  wellbeing  disabilities  Lectures  counselling  Training  earthquake recovery  sustainability  event  community gardens  Community  seminar  Awards  stress  Community Groups  mens health  research  arts  smokefree  culture  men  exercise  migrants  community event  education  environment  resilience  human rights  health  medical  business  sport  conferences  survey  mental wellbeing  Courses  obesity  elderly  support group  environmental health  healthy food  health promotion  violence  pacific health  resources  rebuild  women  race relations  meeting  gardens  workshop  services  leadership  forum  water  disabled  repair  transport  prevention  pacific  dance  fundraising  asian health  sexual health  inequality  cancer  support  disasters  development  mindfulness  dementia  presentation  collaboration  health in all policies  data analysis  recovery  smoking  law  drugs and alcohol  technology  safety  cycling  Sleep  policy  parenting  media  hearing  walking  land  neighbours  social justice  qualification  resilient cities  information  community connection  consultation  oral health  bullying  depression  youth empowerment  young people  activities  non-profit  charity  harm  NURSES  addiction  disease  Communication  alcohol  symposium  submission  anxiety  accessibility  Relationships  eating  economics  Advocacy  eLearning  falls  parking  energy  efficiency  heating  insulation  advice  Eating Disorders  abuse  waste  Matariki  webinar  diabetes  workplace  Film  Climate Change  solutions  urban  management  economy  plan  restoration  Report  Vulnerability  welfare  parks  learning  awareness  emergencies  legislation  injury prevention  reading  Meeting Room  conservation  language  refugees  recreation  built environment  data  venue  urban design  Food  older people  finances  suicide  heritage  gender  recycling  breastfeeding  public  identity  Nursing  submissions  Rainbow  biodiversity  campaign  promotion  Gut Health  diversity  therapy  older adults  sexuality  computing  pollution  School Holidays  Arts Therapy  providers  gambling  Maori health  Cervical cancer  screening  trauma  autism  Governance  treaty of waitangi  care  mentoring  pets  relaxation  Professional Development  pornography  exhibition  history  discrimination  vaping  equity  lockdown  grief  rural  hygiene  participation  tourism  summer  intervention  warning  podcast  science  petition  swimming  roadworks  traffic  wildlife  beaches  pools  immunisation  vaccination  brain  preparation  open day  market  evaluation  noise  music  property  testing  crafts 

More COVID medicines for most at-risk New Zealanders

Thursday, March 31, 2022   Posted in: Signatory Notice Board By: Administrator With tags: disease, medical

Beehive media release: 31st March 2022

New Zealand is boosting its comprehensive suite of medicines to treat COVID-19 with the arrival in the country of one medication, Paxlovid, and the securing of access to the country’s first pre-exposure prophylactic treatment, Health Minister Andrew Little has announced.

“Two years ago, at the start of the pandemic, we had no vaccines or medicines to specifically treat COVID-19 or prevent it spreading,” Andrew Little said.

“Now, we have four vaccines and 95 per cent of eligible people are vaccinated. And we’ve got four medicines being used in hospitals now to treat people who need it - Baricitinib, Ronapreve, Remdesivir and Tocilizumab.

“From next week we’ll be adding Paxlovid to the mix - pills that people with mild cases who are at the highest risk of becoming seriously unwell can take at home.

“The first shipment of Paxlovid has arrived in New Zealand ahead of schedule and will start being offered to those most at risk from next week, protecting people from getting seriously ill and the health system from being overwhelmed.

“Access to Paxlovid will be tight to make sure it gets to the people who need it most. It will be prescribed by doctors, with factors such as age, disability and being immuno-compromised taken into account.” 

The national medicines-funding agency Pharmac, has also secured access to another medicine called Molnupiravir, which is awaiting Medsafe approval.

“That’s six medicines, and I am very pleased with the news today that Pharmac has secured access to a seventh - AstraZeneca’s Evusheld - which can prevent people who can’t have vaccines from getting COVID-19,” Andrew Little said.

“Evusheld is a pre-exposure prophylactic treatment that can actually stop people developing COVID-19, and if approved by Medsafe, will be an invaluable tool to protect people who can’t have vaccines.

“It means we will have medicines to treat those who need it, from before an infection sets in right through to cases of severe infection. It’s a remarkable achievement in two years, and part of our plan to keep New Zealanders safe as we head into winter.

“The emergence of highly effective vaccines and medicines means we can better manage COVID-19 while reopening our borders and easing restrictions. They mean we can shift our focus towards recovery more secure in the knowledge we have a highly vaccinated population and those most at risk of the virus will also have medicines to help protect them.”

Funding for all COVID medicines comes from the Government’s COVID-19 fund.

Find out more information about New Zealand’s COVID medicines on the Pharmac website.